Patients using it for muscle and joint injuries often report gut improvements early in a protocol, sometimes before noticeable changes at the injury site
Additionally, BPC-157 has demonstrated potential in addressing gastrointestinal issues such as inflammatory bowel disease (IBD)
Validated mapping places the receptor in the arcuate and paraventricular nuclei of the hypothalamus, the area postrema, and the nucleus of the solitary tract in the brainstem, regions that govern hunger, satiety, and nausea
Without writing a book and explaining every single trial in detail, Ill share the key takeaway points: Trials #1-4 demonstrated an excellent safety profile in which AOD-9604 was well-tolerated and safe, with next to no difference compared to a placebo Trial #5 saw patients taking the AOD-9604 peptide lose 2.8 kg on a dose of 1 mg, compared to the placebo group losing 0.8 kg over the same time period
One of the common ways it is provided is via a subcutaneous injection in fat deposits in the body
[DOI] [PubMed] [Google Scholar] 13.Dilokthornsakul W., Dhippayom T., Dilokthornsakul P